メディカルアフェアーズ本部

発表論文・寄稿

• Pathol Int (2023) DOI:10.1111/pin.13288

  Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection

  K. Yorozu, M. Kurasawa, Y. Iino, Y. Nakamura, K. Hashizume, N. Harada, A. Ochiai

• Pediatr Blood Cancer (2023) DOI:10.1002/pbc.30590

  Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A

  M. Takeyama, N. Matsumoto, H. Abe, S. Harada, K. Ogiwara, S. Furukawa, N. Shimonishi, Y. Nakajima, K. Yada, T. Soeda, K. Nogami

• J Neuroimmunol (2023) DOI:10.1016/j.jneuroim.2023.578109

  Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice

  K. Serizawa, S. Miyake, Y. Katsura, K. Yorozu, M. Kurasawa, H. Tomizawa-Shinohara, H. Yasuno, Y. Matsumoto

• Cell Rep (2023) DOI:10.1016/j.celrep.2023.112162

  Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade

  A. Mitsuhashi, K. Koyama, H. Ogino, T. Afroj, N. T. Nguyen, H. Yoneda, K. Otsuka, M. Sugimoto, O. Kondoh, H. Nokihara, M. Hanibuchi, H. Takizawa, T. Shinohara, Y. Nishioka

• TH Open (2023) DOI:10.1055/a-2122-7887

  Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan

  N. Matsumoto, H. Abe, R. Kawasaki, Y. Tashiro, M. Noguchi-Sasaki, S. Harada, K. Yoneyama, T. Niino, T. Soeda, Y. Yoshimura

• Arthritis Res Ther (2023) DOI:10.1186/s13075-022-02982-9

  Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis

  K. Matsumoto, K. Suzuki, H. Yoshida, M. Magi, Y. Matsumoto, M. Noguchi-Sasaki, K. Yoshimoto, T. Takeuchi, Y. Kaneko

• Autoimmun Rev (2023) DOI:10.1016/j.autrev.2023.103271

  Longitudinal monitoring of circulating immune cell phenotypes in anti-neutrophil cytoplasmic antibody-associated vasculitis

  K. Matsumoto, K. Suzuki, H. Yasuoka, J. Hirahashi, H. Yoshida, M. Magi, M. Noguchi-Sasaki, Y. Kaneko, T. Takeuchi

• Thromb J (2023) DOI:10.1186/s12959-023-00511-5

  The use of infrared thermography for non-invasive detection of bleeding and musculoskeletal abnormalities in patients with hemophilia: an observational study

  R. Kawasaki, A. Sakata, C. Hosoda, S. Harada, T. Soeda, Y. Nishida, N. Matsumoto, K. Tatsumi, K. Nogami, Y. Yoshimura, M. Shima

• Leuk Lymphoma (2023) DOI:10.1080/10428194.2023.2243531

  Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models

  N. Kawasaki, M. Tomita, Y. Yamashita-Kashima, Y. Yoshimura, S. Yoshiura

• Int J Hematol (2022) DOI:10.1007/s12185-022-03320-0

  Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors

  Y. Yamashita-Kashima, K. Yorozu, T. Fujimura, N. Kawasaki, M. Kurasawa, S. Yoshiura, N. Harada, O. Kondoh, Y. Yoshimura

• Bone (2022) DOI:10.1016/j.bone.2021.116309

  Combination treatment with ibandronate and eldecalcitol prevents osteoporotic bone loss and deterioration of bone quality characterized by nano-arrangement of the collagen/apatite in an ovariectomized aged rat model

  R. Ozasa, M. Saito, T. Ishimoto, A. Matsugaki, Y. Matsumoto, T. Nakano

• Bone (2022) DOI:10.1016/j.bone.2021.116261

  Bone fragility via degradation of bone quality featured by collagen/apatite micro-arrangement in human rheumatic arthritis

  R. Ozasa, A. Matsugaki, T. Ishimoto, S. Kamura, H. Yoshida, M. Magi, Y. Matsumoto, K. Sakuraba, K. Fujimura, H. Miyahara, T. Nakano

• Autoimmun Rev (2022) DOI:10.1016/j.autrev.2022.103160

  Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis

  K. Matsumoto, K. Suzuki, H. Yoshida, M. Magi, Y. Kaneko, T. Takeuchi

• Clin Exp Metastasis (2022) DOI:10.1007/s10585-021-10135-6

  PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8(+) T cells in hematogenous metastasis model with lymphocyte infusion

  C. Masuda, M. Morinaga, D. Wakita, K. Yorozu, M. Kurasawa, M. Sugimoto, O. Kondoh

• Mol Biol Rep (2022) DOI:10.1007/s11033-022-07280-w

  Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies

  N. Kawasaki, Y. Yamashita-Kashima, T. Fujimura, S. Yoshiura, N. Harada, O. Kondoh, Y. Yoshimura

• Br J Haematol (2022) DOI:10.1111/bjh.18341

  The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma

  N. Kawasaki, Y. Nishito, Y. Yoshimura, S. Yoshiura

• Calcif Tissue Int (2022) DOI:10.1007/s00223-021-00940-2

  Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae

  T. Ishimoto, M. Saito, R. Ozasa, Y. Matsumoto, T. Nakano

• Oncol Rep (2022) DOI:10.3892/or.2021.8247

  Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1(low) and immune desert‑like mouse tumors

  N. Ishikura, M. Sugimoto, K. Yorozu, M. Kurasawa, O. Kondoh

• Anticancer Drugs (2022) DOI:10.1097/cad.0000000000001249

  Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells

  K. Furugaki, N. Harada, Y. Yoshimura

• Thromb Haemost (2021) DOI:10.1055/s-0041-1725009

  Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A

  M. Takeyama, S. Furukawa, K. Yada, K. Ogiwara, N. Shimonishi, Y. Nakajima, K. Mizumachi, M. Noguchi-Sasaki, M. Shima, K. Nogami

• Autoimmun Rev (2021) DOI:10.1016/j.autrev.2021.102884

  Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis

  T. Takeuchi, H. Yoshida, S. Tanaka

• Neurol Neuroimmunol Neuroinflamm (2021) DOI:10.1212/nxi.0000000000001076

  New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD

  Y. Takeshita, S. Fujikawa, K. Serizawa, M. Fujisawa, K. Matsuo, J. Nemoto, F. Shimizu, Y. Sano, H. Tomizawa-Shinohara, S. Miyake, R. M. Ransohoff, T. Kanda

• Inflamm Regen (2021) DOI:10.1186/s41232-021-00184-5

  Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders

  K. Serizawa, H. Tomizawa-Shinohara, S. Miyake, K. Yogo, Y. Matsumoto

• Int J Hematol (2021) DOI:10.1007/s12185-021-03108-8

  Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor

  Y. Nakajima, H. Tonegawa, M. Noguchi-Sasaki, K. Nogami

• Clin Transl Immunology (2021) DOI:10.1002/cti2.1307

  Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis

  K. Matsumoto, K. Suzuki, K. Yoshimoto, S. Ishigaki, H. Yoshida, M. Magi, Y. Matsumoto, Y. Kaneko, T. Takeuchi

• J Thromb Haemost (2021) DOI:10.1111/jth.15506

  Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A

  M. Kaneda, R. Kawasaki, N. Matsumoto, H. Abe, Y. Tashiro, Y. Inokuchi, H. Yasuno, M. Sasaki-Noguchi, T. Soeda, Y. Yoshimura, T. Oka

• Sci Rep (2021) DOI:10.1038/s41598-021-93113-y

  Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

  T. Iwai, M. Sugimoto, N. S. Patil, D. Bower, M. Suzuki, C. Kato, K. Yorozu, M. Kurasawa, D. S. Shames, O. Kondoh

• Mol Cancer Ther (2021) DOI:10.1158/1535-7163.Mct-21-0031

  Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy

  T. Iwai, M. Sugimoto, H. Patel, K. Yorozu, M. Kurasawa, O. Kondoh

• Mol Cancer Ther (2021) DOI:10.1158/1535-7163.Mct-20-0864

  Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

  T. Fujimura, Y. Yamashita-Kashima, N. Kawasaki, S. Yoshiura, N. Harada, Y. Yoshimura

• J Immunol (2021) DOI:10.4049/jimmunol.2000909

  Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes

  T. Afroj, A. Mitsuhashi, H. Ogino, A. Saijo, K. Otsuka, H. Yoneda, M. Tobiume, N. T. Nguyen, H. Goto, K. Koyama, M. Sugimoto, O. Kondoh, H. Nokihara, Y. Nishioka

学会発表

• ECTRIMS 2023 (2023)

  Clarification of blood-retinal barrier on AQP4-peptide immunized mice

  Y Katsura et al.

• 第51回日本臨床免疫学会総会 (2023)

  末梢血RNAseqを用いた網羅的遺伝子発現解析による成人スチル病疾患活動性評価指標構築の試み

  M Magi et al.

• WMS 2023 (2023)

  Anti-IL-6 receptor antibody suppresses muscle atrophy in human myotube cells

  S Miyake et al.

• 第35回日本神経免疫学会学術集会 (2023)

  抗IL-6受容体抗体はヒト筋管細胞における筋萎縮を抑制する

  S Miyake et al.

• 第35回日本神経免疫学会学術集会 (2023)

  抗IL-6受容体抗体はAQP4ペプチド免疫により誘導される自己免疫性脳脊髄炎の発症を抑制する

  K Serizawa et al.

• 第27回日本がん免疫学会総会 (2023)

  抗PD-L1抗体と抗TIGIT抗体の併用治療による抗腫瘍効果とその作用機序の解析

  M Morinaga, T Funaki et al.

• 第18回日本がん分子標的治療学会TRワークショップ (2023)

  ALK陽性肺癌細胞株を用いたdrug-tolerant persisterの同定とFGFR1阻害剤との併用による耐性克服

  K Furugaki et al.

• ASH 2022 (2022)

  Retreatment with Polatuzumab Vedotin in Combination with Rituximab Increases Antitumor Activity Against Polatuzumab Vedotin-Resistant DLBCL Cells

  M Tomita et al.

• 第51回日本免疫学会学術集会 (2022)

  AQP4 peptide immunization induces neurological disease with clinical features of neuromyelitis optica spectrum disorder in mice

  S Miyake et al.

• 第63回日本肺癌学会学術集会 (2022)

  患者由来 ALK 融合遺伝子陽性肺がん細胞株を用いた drug tolerant persister に対する新規併用療法の探索

  T Fujimura et al.

• ECTRIMS 2022 (2022)

  IL-6 receptor antagonism prevents neurological disease in mice with AQP4 peptide immunization

  K Serizawa et al.

• 第34回日本神経免疫学会学術集会 (2022)

  AQP4ペプチド免疫により誘導される自己免疫性脳脊髄炎モデルマウスの病態解析

  K Serizawa et al.

• ISTH 2022 (2022)

  Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan

  N Matsumoto et al.

• 第44回日本血栓止血学会学術集会 (2022)

  エミシズマブの国内治験で得られたレポジトリー検体を用いた抗エミシズマブ抗体の特性解析

  H Abe et al.

• AACR 2022 (2022)

  The combination of polatuzumab vedotin with rituximab increases antitumor activity against polatuzumab vedotin-refractory lymphoma

  N Kawasaki et al.

• 第62回日本肺癌学会学術集会 (2021)

  抗PD-L1抗体は血行性脳転移異種移植モデルへのリンパ球移入評価系において脳転移巣への抗腫瘍効果を示した

  M Morinaga et al.

• 第33回日本神経免疫学会学術集会 (2021)

  AQP4ペプチド免疫による新規NMOSDマウスモデルの作出と評価

  S Miyake et al.

• ECTRIMS 2021 (2021)

  Characterization of a neuromyelitis optica mice model induced by AQP4 peptide immunization

  K Serizawa et al.

• 第83回日本血液学会学術集会 (2021)

  Obinutuzumab誘導性ADCC耐性機序および併用療法有用性に関する検討

  N Kawasaki et al.

• 第83回日本血液学会学術集会 (2021)

  オビヌツズマブ耐性モデルにおけるオビヌツズマブとベンダムスチンの併用効果検討

  Y Yamashita et al.

• 第25回日本がん免疫学会総会 (2021)

  がん免疫療法に関する非臨床育薬研究

  M Sugimoto et al.

• 第25回日本がん分子標的治療学会学術総会 (2021)

  がん免疫療法に関する非臨床育薬研究からの効果予測バイオマーカー同定の試み

  M Sugimoto et al.

• 第65回日本リウマチ学会総会・学術集会 (2021)

  関節リウマチ患者のトシリズマブ治療によるregulatory T細胞分画の挙動解析

  H Yoshida et al.